STAT Plus: 2018’s comeback kid: Endocyte goes from nosedive to Novartis’ latest acquisition
ADOBE
Last year, Endocyte laid off nearly half the company. This year, shareholders voted to approve a $2.1 billion acquisition offer from Novartis.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario